EPIREAD Trademark

Trademark Overview


On Friday, February 2, 2024, a trademark application was filed for EPIREAD with the United States Patent and Trademark Office. The USPTO has given the EPIREAD trademark a serial number of 98977343. The federal status of this trademark filing is SU - NON-FINAL ACTION - MAILED as of Tuesday, January 6, 2026. This trademark is owned by Moonwalk Biosciences. The EPIREAD trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the field of pharmaceuticals, therapeutics, and biotechnology; Conducting research and clinical trials for others relating to pharmaceuticals in the fields of age-related, autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, pediatric, psychiatric, pulmonary, renal, reproductive, respiratory, and skeletal diseases; Conducting research and clinical trials for others relating to veterinary pharmaceuticals in the fields of age-related, autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, psychiatric, pulmonary, renal, rep...
epiread

General Information


Serial Number98977343
Word MarkEPIREAD
Filing DateFriday, February 2, 2024
Status807 - SU - NON-FINAL ACTION - MAILED
Status DateTuesday, January 6, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 7, 2025

Trademark Statements


Goods and ServicesResearch and development in the field of pharmaceuticals, therapeutics, and biotechnology; Conducting research and clinical trials for others relating to pharmaceuticals in the fields of age-related, autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, pediatric, psychiatric, pulmonary, renal, reproductive, respiratory, and skeletal diseases; Conducting research and clinical trials for others relating to veterinary pharmaceuticals in the fields of age-related, autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, psychiatric, pulmonary, renal, reproductive, respiratory, and skeletal diseases

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, February 29, 2024
Primary Code042
First Use Anywhere DateTuesday, May 7, 2024
First Use In Commerce DateTuesday, May 7, 2024

Trademark Owner History


Party NameMoonwalk Biosciences
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Party NameMoonwalk Biosciences
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events


Event DateEvent Description
Tuesday, February 6, 2024NEW APPLICATION ENTERED
Thursday, February 29, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, May 22, 2024ASSIGNED TO EXAMINER
Thursday, May 23, 2024NON-FINAL ACTION WRITTEN
Thursday, May 23, 2024NON-FINAL ACTION E-MAILED
Thursday, May 23, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 19, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, August 19, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 19, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 27, 2024FINAL REFUSAL WRITTEN
Tuesday, August 27, 2024FINAL REFUSAL E-MAILED
Tuesday, August 27, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, October 30, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, October 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 12, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, December 12, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, December 12, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, December 12, 2024EXAMINER'S AMENDMENT ENTERED
Thursday, December 12, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 1, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 7, 2025PUBLISHED FOR OPPOSITION
Tuesday, January 7, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 4, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, July 11, 2025TEAS STATEMENT OF USE RECEIVED
Friday, July 11, 2025TEAS REQUEST TO DIVIDE RECEIVED
Monday, January 5, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, July 11, 2025DIVISIONAL REQUEST RECEIVED
Monday, January 5, 2026DIVISIONAL PROCESSING COMPLETE
Saturday, July 11, 2026USE AMENDMENT FILED
Monday, January 5, 2026STATEMENT OF USE PROCESSING COMPLETE
Tuesday, January 6, 2026SU - NON-FINAL ACTION - WRITTEN
Tuesday, January 6, 2026NON-FINAL ACTION E-MAILED
Tuesday, January 6, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED